C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 307/54 (2006.01) A61K 31/34 (2006.01) A61K 31/341 (2006.01) A61K 31/395 (2006.01) A61K 31/4178 (2006.01) C07D 307/58 (2006.01) C07D 405/14 (2006.01)
Patent
CA 2204898
The present invention provides methods for treating Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium parvum in a subject in need of such treatment. The methods comprise administering to the subject a compound of formula (I), wherein R1 and R2 are each independently selected from the group consisting of H, loweralkyl, aryl, alkylaryl, aminoalkyl, aminoaryl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl; R3 and R4 are each independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkylaryl, aryl, oxyaryl, aminoalkyl, aminoaryl, or halogen; and X and Y are located in the para or meta positions and are selected from the group consisting of H, loweralkyl, oxyalkyl, and (a) wherein each R5 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl or two R5 groups together represent C2-C10 alkyl, hydroxyalkyl, or alkylene; and R6 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aryl, or alkylaryl; or a pharmaceutically acceptable salt thereof. The compounds are administered in an amount effective to treat the condition. The present invention also includes novel compounds useful in the treatment of Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium parvum.
La présente invention décrit des méthodes pour le traitement de la pneumonie à Pneumocystis carinii, de la Giardia lamblia, et du Cryptosporidium parvum chez les personnes nécessitant pareil traitement. Les méthodes présentées consistent à administrer un composé de la formule (I), où: R1 et R2 sont choisis indépendamment dans le groupe comprenant H, alkyle inférieur, aryle, alkylaryle, aminoalkyle, aminoaryle, halogène, oxyalkyle, oxyaryle, ou oxyarylalkyle; R3 et R4 sont choisis indépendamment dans le groupe comprenant H, alkyle inférieur, oxyalkyle, alkylaryle, aryle, oxyaryle, aminoalkyle, aminoaryle, ou halogène; et X et Y occupent les positions para ou meta, et sont chosisis dans le groupe comprenant H, alkyle inférieur, oxyalkyle, et (a), où: chaque élément R5 est choisi indépendamment dans le groupe comprenant H, alkyle inférieur, alcoxyalkyle, hydroxyalkyle, aminoalkyle, alkylaminoalkyle, cycloalkyle, aryle, ou alkylaryle, ou bien deux groupes R5 représentent ensemble C2-C10 alkyle, hydroxyalkyle, ou alkylène; et R6 correspond à H, hydroxy, alkyle inférieur, alcoxyalkyle, hydroxyalkyle, aminoalkyle, alkylamino, alkylaminoalkyle, cycloalkyle, hydroxycycloalkyle, alcoxycycloalkyle, aryle ou alkylaryle; ou un sel pharmaceutiquement acceptable de ces composés. Ces composés sont administrés dans des proportions efficaces pour le traitement de l'affection considérée. En outre, la présente invention décrit de nouveaux composés utiles pour le traitement de la pneumonie à Pneumocystis carinii, de la Giardia lamblia, et du Cryptosporidium parvum.
Blagburn Byron L.
Boykin David W.
Dykstra Christine C.
Hall James E.
Kumar Arvind
Auburn University
Georgia State University Research Foundation Inc.
Sim & Mcburney
The University Of North Carolina At Chapel Hill
LandOfFree
Methods of inhibiting pneumocystis carini pneumonia, giardia... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting pneumocystis carini pneumonia, giardia..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting pneumocystis carini pneumonia, giardia... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1417244